Androgens and estrogens in skeletal sexual dimorphism

Asian Journal of Andrology

Volumn 16, Issue 2, 2014, Pages 213-222

  Laurent, Michaël ^a,b   Antonio, Leen ^a,b   Sinnesael, Mieke ^a   Dubois, Vanessa ^a   Gielen, Evelien ^a,b   Classens, Frank ^a   Vanderschueren, Dirk ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Androgen receptor; Bone mineral density; Estradiol; Estrogen receptor; Male; Osteoblast; Osteoclast; Osteocyte; Osteoporosis; Sex hormone binding globulin; Testosterone

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; SEX HORMONE BINDING GLOBULIN;

BONE MASS; BONE STRENGTH; BONE TURNOVER; CORTICAL BONE; HUMAN; KNOCKOUT MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOPOROSIS; REVIEW; SEX DIFFERENCE; SIGNAL TRANSDUCTION; TRABECULAR BONE;

ANDROGENS; BONE AND BONES; BONE DENSITY; ESTROGENS; FEMALE; HUMANS; MALE; SEX CHARACTERISTICS;

EID: 84896785220     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.122356     Document Type: Review

References (189)

1. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, et al. Androgens and bone. Endocr Rev 2004; 25: 389-425. (Pubitemid 38786452)
2. Laurent M, Gielen E, Claessens F, Boonen S, Vanderschueren D. Osteoporosis in older men: recent advances in pathophysilogy and treatment. Best Pract Res Clin Endocrinol Meab 2013; 27: 527-9.
3. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17: 1726-33. (Pubitemid 44607392)
4. Kanis Ja, Oden A, Mccloskey EV, Johansson H, Wahl DA, et al. IOF Working Group on Epidemiology and Quality of Life. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 2012; 23: 2239-56.
5. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22: 465-75. (Pubitemid 46797130)
6. Tarride JE, Guo N, Hopkins R, Leslie WD, Morin S, et al. The burden of illness of osteoporosis in Canadian men. J Bone Miner Res 2012; 27: 1830-8.
7. Tarride JE, Hopkins RB, Leslie WD, Morin S, Adachi JD, et al. The burden of illness of osteoporosis in Canada. Osteoporos Int 2012; 23: 2591-600.
8. Frost M, Wraae K, Abrahamsen B, Hoiberg M, Hagen C, et al. Osteoporosis and vertebral fractures in men aged 60-74 years. Age Ageing 2012; 41: 171-7.
9. Nurmi-Luthje I, Sund R, Juntunen M, Luthje P. Post-hip fracture use of prescribed calcium plus vitamin d or vitamin d supplements and antiosteoporotic drugs is associated with lower mortality: a nationwide study in Finland. J Bone Miner Res 2011; 26: 1845-53.
10. Wastesson JW, Ringback Weitoft G, Parker MG, Johnell K. educational level and use of osteoporosis drugs in elderly men and women: a Swedish nationwide register-based study. Osteoporos Int 2013; 24: 433-42.
11. Curtis JR, Mcclure LA, Delzell E, Howard VJ, Orwoll E, et al. Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med 2009; 24: 956-62.
12. Shibli-Rahhal A, Vaughan-Sarrazin MS, Richardson K, Cram P. Testing and treatment for osteoporosis following hip fracture in an integrated U.S. healthcare delivery system. Osteoporos Int 2011; 22: 2973-80.
13. Callewaert F, Boonen S, Vanderschueren D. Sex steroids and the male skeleton: a tale of two hormones. Trends Endocrinol Metab 2010; 21: 89-95.
14. Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, et al. FSH directly regulates bone mass. Cell 2006; 125: 247-60.
15. Zhu LL, Blair H, Cao J, Yuen T, Latif R, et al. Blocking antibody to the beta-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesis. Proc Natl Acad Sci U S A 2012; 109: 14574-9.
16. Yarram SJ, Perry MJ, Christopher TJ, Westby K, Brown NL, et al. Luteinizing hormone receptor knockout (Lurko) mice and transgenic human chorionic gonadotropin (Hcg)-overexpressing mice (Hcg Alphabeta+) have bone phenotypes. Endocrinology 2003; 144: 3555-64. (Pubitemid 36904435)
17. Seibel MJ, Dunstan CR, Zhou H, Allan CM, Handelsman DJ. Sex steroids, not FSH, influence bone mass. Cell 2006; 127: 1079. (Pubitemid 44894538)
18. Allan CM, Kalak R, Dunstan CR, Mctavish KJ, Zhou H, et al. Follicle-stimulating hormone increases bone mass in female mice. Proc Natl Acad Sci U S A 2010; 107: 22629-34.
19. Rouach V, Katzburg S, Koch Y, Stern N, Somjen D. Bone loss in ovariectomized rats: dominant role for estrogen but apparently not for FSH. J Cell Biochem 2011; 112: 128-37.
20. Uihlein A, Kumbhani R, Siwila-Sackman E, Finkelstein J, Lee H, et al. FSH suppression in eugonadal men does not change bone turnover markers. J Bone Miner Res 2012; 27.
21. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981; 53: 58-68. (Pubitemid 13245381)
22. Mendel CM. The free hormone hypothesis: a physiologically based mathematical model. Endocr Rev 1989; 10: 232-74. (Pubitemid 19223060)
23. Caldwell JD, Jirikowski GF. Sex hormone binding globulin and aging. Horm Metab Res 2009; 41: 173-82.
24. Helsen C, Kerkhofs S, Clinckemalie L, Spans L, Laurent M, et al. Structural basis for nuclear hormone receptor DNA binding. Mol Cell Endocrinol 2012; 348: 411-7.
25. Schauwaers K, De Gendt K, Saunders PT, Atanassova N, Haelens A, et al. Loss of androgen receptor binding to selective androgen response elements causes a reproductive phenotype in a knockin mouse model. Proc Natl Acad Sci U S A 2007; 104: 4961-6. (Pubitemid 47186159)
26. Callewaert F, Sinnesael M, Gielen E, Boonen S, Vanderschueren D. Skeletal sexual dimorphism: relative contribution of sex steroids, GH-IGF1, and mechanical loading. J Endocrinol 2010; 207: 127-34.
27. Ophoff J, Callewaert F, Venken K, De Gendt K, Ohlsson C, et al. Physical activity in the androgen receptor knockout mouse: evidence for reversal of androgen deficiency on cancellous bone. Biochem Biophys Res Commun 2009; 378: 139-44.
28. Rana K, Fam BC, Clarke MV, Pang TP, Zajac JD, et al. Increased adiposity in dna binding-dependent androgen receptor knockout male mice associated with decreased voluntary activity and not insulin resistance. Am J Physiol Endocrinol Metab 2011; 301: E767-78.
29. Boonen S, Dejaeger E, Vanderschueren D, Venken K, Bogaerts A, et al. Osteoporosis and osteoporotic fracture occurrence and prevention in the elderly: a geriatric perspective. Best Pract Res Clin Endocrinol Metab 2008; 22: 765-85.
30. Masud T, Binkley N, Boonen S, Hannan MT. Official positions for frax (R) clinical regarding falls and frailty: can falls and frailty be used in frax (R)? from joint official positions development conference of the international society for clinical densitometry and international osteoporosis foundation on frax (R). J Clin Densitom 2011; 14: 194-204.
31. Looker AC, Melton LJ 3rd, Harris T, Borrud L, Shepherd J, et al. Age, gender, and race/ethnic differences in total body and subregional bone density. Osteoporos Int 2009; 20: 1141-9.
32. Meyer HE, Tverdal A, Falch JA. Risk factors for hip fracture in middle-aged norwegian women and men. Am J Epidemiol 1993; 137: 1203-11. (Pubitemid 23205895)
33. Joakimsen RM, Fonnebo V, Magnus JH, Tollan A, Sogaard AJ. The tromso study: body height, body mass index and fractures. Osteoporos Int 1998; 8: 436-42. (Pubitemid 28486711)
34. Bjornerem A, Bui Q, Ghasem-Zadeh A, Hopper JL, Zebaze R, et al. Fracture risk and height: an association partly accounted for by cortical porosity of relatively thinner cortices. J Bone Miner Res 2013; 28: 2017-26.
35. Rudang R, Mellstrom D, Clark E, Ohlsson C, Lorentzon M. Advancing maternal age is associated with lower bone mineral density in young adult male offspring. Osteoporos Int 2011; 23: 475-82.
36. Cooper C, Westlake S, Harvey N, Javaid K, Dennison E, et al. Review: developmental origins of osteoporotic fracture. Osteoporos Int 2006; 17: 337-47.
37. Hernandez CJ, Beaupre GS, Carter Dr. A theoretical analysis of the relative influences of peak BMD, age-related bone loss and menopause on the development of osteoporosis. Osteoporos Int 2003; 14: 843-7. (Pubitemid 37462135)
38. Gafni RI, Baron J. Childhood bone mass acquisition and peak bone mass may not be important determinants of bone mass in late adulthood. Pediatrics 2007; 119 Suppl 2: S131-6. (Pubitemid 46397933)
39. Baxter-Jones AD, Faulkner RA, Forwood MR, Mirwald RL, Bailey DA. Bone mineral accrual from 8 to 30 years of age: an estimation of peak bone mass. J Bone Miner Res 2011; 26: 1729-39.
40. Ohlsson C, Darelid A, Nilsson M, Melin J, Mellstrom D, et al. Cortical consolidation due to increased mineralization and endosteal contraction in young adult men: a five-year longitudinal study. J Clin Endocrinol Metab 2011; 96: 2262-9.
41. Berger C, Goltzman D, Langsetmo L, Joseph L, Jackson S, et al. CaMos Research Group. Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res 2010; 25: 1948-57.
42. Darelid A, Ohlsson C, Nilsson M, Kindblom JM, Mellstrom D, et al. Catch up in bone acquisition in young adult men with late normal puberty. J Bone Miner Res 2012; 27: 2198-207.
43. Burghardt AJ, Kazakia GJ, Ramachandran S, Link TM, Majumdar S. Age-.and gender-related differences in the geometric properties and biomechanical significance of intracortical porosity in the distal radius and tibia. J Bone Miner Res 2010; 25: 983-93.
44. Macdonald HM, Nishiyama KK, Kang J, Hanley DA, Boyd SK. Age-related patterns of trabecular and cortical bone loss differ between sexes and skeletal sites: a population-based HR-pQCT study. J Bone Miner Res 2011; 26: 50-62.
45. Szulc P, Munoz F, Duboeuf F, Marchand F, Delmas PD. Low width of tubular bones is associated with increased risk of fragility fracture in elderly men: the MINOS study. Bone 2006; 38: 595-602.
46. Khosla S, Riggs BL, Atkinson EJ, Oberg AL, Mcdaniel LJ, et al. Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res 2006; 21: 124-31. (Pubitemid 43023234)
47. Dalzell N, Kaptoge S, Morris N, Berthier A, Koller B, et al. Bone micro-architecture and determinants of strength in the radius and tibia: age-related changes in a population-based study of normal adults measured with high-resolution pQCT. Osteoporos Int 2009; 20: 1683-94.
48. Kirmani S, Christen D, van Lenthe GH, Fischer PR, Bouxsein ML, et al. Bone structure at the distal radius during adolescent growth. J Bone Miner Res 2009; 24: 1033-42.
49. Walsh JS, Paggiosi MA, Eastell R. Cortical consolidation of the radius and tibia in young men and women. J Clin Endocrinol Metab 2012; 97: 3342-8.
50. Riggs BL, Melton LJ, Robb RA, Camp JJ, Atkinson EJ, et al. A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res 2008; 23: 205-14. (Pubitemid 351160034)
51. Lauretani F, Bandinelli S, Griswold ME, Maggio M, Semba R, et al. Longitudinal changes in BMD and bone geometry in a population-based study. J Bone Miner Res 2008; 23: 400-8. (Pubitemid 351304670)
52. Duan Y, Beck TJ, Wang XF, Seeman E. Structural and biomechanical basis of sexual dimorphism in femoral neck fragility has its origins in growth and aging. J Bone Miner Res 2003; 18: 1766-74. (Pubitemid 37322553)
53. Riggs BL, Melton Iii LL 3rd, Robb RA, Camp JJ, Atkinson EJ, et al. Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res 2004; 19: 1945-54. (Pubitemid 41103408)
54. Szulc P, Seeman E. Thinking inside and outside the envelopes of bone: dedicated to PDD. Osteoporos Int 2009; 20: 1281-8.
55. Szulc P, Boutroy S, Vilayphiou N, Chaitou A, Delmas PD, et al. Cross-sectional analysis of the association between fragility fractures and bone microarchitecture in older men: the STRAMBO study. J Bone Miner Res 2011; 26: 1358-67.
56. Peacock M, Buckwalter KA, Persohn S, Hangartner TN, Econs MJ, et al. Race and sex differences in bone mineral density and geometry at the femur. Bone 2009; 45: 218-25.
57. Srinivasan B, Kopperdahl DL, Amin S, Atkinson EJ, Camp J, et al. Relationship of femoral neck areal bone mineral density to volumetric bone mineral density, bone size, and femoral strength in men and women. Osteoporos Int 2011; 23: 155-62.
58. Riggs BL, Khosla S, Melton LJ 3rd. A unitary model for involutional osteoporosis: estrogen deficiency causes both type i and type ii osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998; 13: 763-73. (Pubitemid 28224192)
59. Khosla S, Melton LJ 3rd, Riggs BL. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res 2011; 26: 441-51.
60. Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 2010; 31: 266-300.
61. Szulc P, Joly-Pharaboz MO, Marchand F, Delmas PD. Insulin-like growth factor i is a determinant of hip bone mineral density in men less than 60 years of age: MINOS study. Calcif Tissue Int 2004; 74: 322-9. (Pubitemid 38480855)
62. Ohlsson C, Mellstrom D, Carlzon D, Orwoll E, Ljunggren O, et al. Older men with low serum igf-1 have an increased risk of incident fractures: the MROS sweden study. J Bone Miner Res 2011; 26: 865-72.
63. Boonen S, Pye SR, O'neill TW, Szulc P, Gielen E, et al. EMAS Group. Influence of bone remodelling rate on quantitative ultrasound parameters at the calcaneus and dxa bmda of the hip and spine in middle-aged and elderly european men: The European Male Ageing Study (EMAS). Eur J Endocrinol 2011; 165: 977-86.
64. Pye SR, Almusalam B, Boonen S, Vanderschueren D, Borghs H, et al. EMAS Study Group. Influence of insulin-like growth factor binding protein (igfbp)-1 and igfbp-3 on bone health: results from the European Male Ageing Study. Calcif Tissue Int 2011; 88: 503-10.
65. Curtis JR, Ewing SK, Bauer DC, Cauley JA, Cawthon PM, et al. Association of intact parathyroid hormone levels with subsequent hip BMD loss: The Osteoporotic Fractures in men (MROs) study. J Clin Endocrinol Metab 2012; 97: 1937-44.
66. Grundberg E, Lau EM, Pastinen T, Kindmark A, Nilsson O, et al. Vitamin d receptor 3' haplotypes are unequally expressed in primary human bone cells and associated with increased fracture risk: The MROS study in Sweden and Hong Kong. J Bone Miner Res 2007; 22: 832-40. (Pubitemid 351339743)
67. Vanderschueren D, Pye SR, O'neill TW, Lee DM, Jans I, et al. EMAS Study Group. Active vitamin d (1,25-dihydroxyvitamin d) and bone health in middle-aged and elderly men: The European Male Aging Study (EMAS). J Clin Endocrinol Metab 2013; 98: 995-1005.
68. Roef G, Lapauw B, Goemaere S, Zmierczak H, Fiers T, et al. thyroid hormone status within the physiological range affects bone mass and density in healthy men at the age of peak bone mass. Eur J Endocrinol 2011; 164: 1027-34.
69. Waring AC, Harrison S, Fink HA, Samuels MH, Cawthon PM, et al. Osteoporotic Fractures in Men (MrOS) Study. A prospective study of thyroid function, bone loss, and fractures in older men: The MROS study. J Bone Miner Res 2013; 28: 472-9.
70. Rolland T, Boutroy S, Vilayphiou N, Blaizot S, Chapurlat R, et al. Poor trabecular microarchitecture at the distal radius in older men with increased concentration of high-sensitivity c-reactive protein: The STRAMBO study. Calcif Tissue Int 2012; 90: 496-506.
71. Roshandel D, Holliday KL, Pye SR, Boonen S, Borghs H, et al. EMAS Study Group. Genetic variation in the rankl/rank/opg signaling pathway is associated with bone turnover and bone mineral density in men. J Bone Miner Res 2010; 25: 1830-8.
72. Roshandel D, Holliday KL, Pye SR, Ward KA, Boonen S, et al. EMAS Study Group. Influence of polymorphisms in the RANKL/RANK/OPG signaling pathway on volumetric bone mineral density and bone geometry at the forearm in men. Calcif Tissue Int 2011; 89: 446-55.
73. Roshandel D, Thomson W, Pye SR, Boonen S, Borghs H, et al. EMAS Study Group. Polymorphisms in genes involved in the NF-kB signalling pathway are associated with bone mineral density, geometry and turnover in men. Plos One 2011; 6: e28031.
74. Liu CT, Estrada K, Yerges-Armstrong LM, Amin N, Evangelou E, et al. Assessment of gene-by-sex interaction effect on bone mineral density. J Bone Miner Res 2012; 27: 2051-64.
75. Van Caenegem E, Wierckx K, Taes Y, Dedecker D, Van De Peer F, et al. Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy. J Clin Endocrinol Metab 2012; 97: 2503-11.
76. Taes Y, Lapauw B, Vandewalle S, Zmierczak H, Goemaere S, et al. Estrogen-specific action on bone geometry and volumetric bone density: longitudinal observations in an adult with complete androgen insensitivity. Bone 2009; 45: 392-7.
77. Han TS, Goswami D, Trikudanathan S, Creighton SM, Conway GS. Comparison of bone mineral density and body proportions between women with complete androgen insensitivity syndrome and women with gonadal dysgenesis. Eur J Endocrinol 2008; 159: 179-85.
78. Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA, et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 2007; 282: 27285-97. (Pubitemid 47501960)
79. Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, et al. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest 1995; 95: 2886-95.
80. Hofbauer LC, Ten RM, Khosla S. The anti-androgen hydroxyflutamide and androgens inhibit interleukin-6 production by an androgen-responsive human osteoblastic cell line. J Bone Miner Res 1999; 14: 1330-7. (Pubitemid 29368295)
81. Callewaert F, Venken K, Kopchick JJ, Torcasio A, van Lenthe GH, et al. Sexual dimorphism in cortical bone size and strength but not density is determined by independent and time-specific actions of sex steroids and IGF-1: evidence from pubertal mouse models. J Bone Miner Res 2010; 25: 617-26.
82. Perry RJ, Farquharson C, Ahmed SF. The role of sex steroids in controlling pubertal growth. Clin Endocrinol (Oxf) 2008; 68: 4-15. (Pubitemid 350243472)
83. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331: 1056-61. (Pubitemid 24317698)
84. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997; 337: 91-5. (Pubitemid 27284394)
85. Bilezikian JP, Morishima A, Bell J, Grumbach MM. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 1998; 339: 599-603. (Pubitemid 28385657)
86. Bouillon R, Bex M, Vanderschueren D, Boonen S. Estrogens are essential for male pubertal periosteal bone expansion. J Clin Endocrinol Metab 2004; 89: 6025-9. (Pubitemid 39628410)
87. Merlotti D, Gennari L, Stolakis K, Nuti R. Aromatase activity and bone loss in men. J Osteoporos 2011; 2011: 230671.
88. Borjesson AE, Windahl SH, Karimian E, Eriksson EE, Lagerquist MK, et al. The role of estrogen receptor-alpha and its activation function-1 for growth plate closure in female mice. Am J Physiol Endocrinol Metab 2012; 302: E1381-9.
89. Zachmann M, Prader A, Sobel EH, Crigler JF Jr, Ritzen EM, et al. pubertal growth in patients with androgen insensitivity: indirect evidence for the importance of estrogens in pubertal growth of girls. J Pediatr 1986; 108: 694-7. (Pubitemid 16064111)
90. Callewaert F, Venken K, Ophoff J, De Gendt K, Torcasio A, et al. Differential regulation of bone and body composition in male mice with combined inactivation of androgen and estrogen receptor-alpha. FASEB J 2009; 23: 232-40.
91. Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis. JAMA 1941; 116: 2465-74.
92. Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI, et al. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 1987; 106: 354-61. (Pubitemid 17029484)
93. Swartz CM, Young MA. Male hypogonadism and bone fracture. N Engl J Med 1988; 318: 996. (Pubitemid 18095002)
94. Slemenda CW, Longcope C, Zhou L, Hui SL, Peacock M, et al. Sex steroids and bone mass in older men. Positive Associations with serum estrogens and negative associations with androgens. J Clin Invest 1997; 100: 1755-9. (Pubitemid 27431332)
95. Khosla S, Melton LJ 3rd, Atkinson EJ, O'fallon WM, Klee GG, et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998; 83: 2266-74. (Pubitemid 28503012)
96. Khosla S, Melton LJ 3rd, Atkinson EJ, O'fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001; 86: 3555-61. (Pubitemid 32755943)
97. Szulc P, Munoz F, Claustrat B, Garnero P, Marchand F, et al. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab 2001; 86: 192-9. (Pubitemid 32109796)
98. Gennari L, Merlotti D, Martini G, Gonnelli S, Franci B, et al. Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab 2003; 88: 5327-33. (Pubitemid 37452735)
99. Szulc P, Uusi-Rasi K, Claustrat B, Marchand F, Beck TJ, et al. Role of sex steroids in the regulation of bone morphology in men. The MINOS study. Osteoporos Int 2004; 15: 909-17. (Pubitemid 39506458)
100. Goderie-Plomp HW, van der Klift M, De Ronde W, Hofman A, de jong FH, et al. Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: The Rotterdam Study. J Clin Endocrinol Metab 2004; 89: 3261-9. (Pubitemid 38951891)
101. Khosla S, Melton LJ 3rd, Robb RA, Camp JJ, Atkinson EJ, et al. Relationship of volumetric bmd and structural parameters at different skeletal sites to sex steroid levels in men. J Bone Miner Res 2005; 20: 730-40. (Pubitemid 40571629)
102. Vandenput L, Labrie F, Mellstrom D, Swanson C, Knutsson T, et al. Serum levels of specific glucuronidated androgen metabolites predict bmd and prostate volume in elderly men. J Bone Miner Res 2007; 22: 220-7. (Pubitemid 46167792)
103. Kuchuk NO, van Schoor NM, Pluijm SM, Smit JH, de Ronde W, et al. The association of sex hormone levels with quantitative ultrasound, bone mineral density, bone turnover and osteoporotic fractures in older men and women. Clin Endocrinol (Oxf) 2007; 67: 295-303. (Pubitemid 47076310)
104. Araujo AB, Travison TG, Leder BZ, Mckinlay JB. Correlations between serum testosterone, estradiol, and sex hormone-binding globulin and bone mineral density in a diverse sample of men. J Clin Endocrinol Metab 2008; 93: 2135-41. (Pubitemid 351831527)
105. Vanderschueren D, Pye SR, Venken K, Borghs H, Gaytant J, et al. EMAS Study Group. Gonadal sex steroid status and bone health in middle-aged and elderly european men. Osteoporos Int 2010; 21: 1331-9.
106. Mellstrom D, Vandenput L, Mallmin H, Holmberg AH, Lorentzon M, et al. Older men with low serum estradiol and high serum shbg have an increased risk of fractures. J Bone Miner Res 2008; 23: 1552-60.
107. Ward KA, Pye SR, Adams JE, Boonen S, Vanderschueren D, et al. EMAS Study Group. Influence of age and sex steroids on bone density and geometry in middle-aged and elderly european men. Osteoporos Int 2011; 22: 1513-23.
108. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, et al. EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 363: 123-35.
109. Vandenput L, Boonen S, Van Herck E, Swinnen JV, Bouillon R, et al. Evidence from the aged orchidectomized male rat model that 17beta-estradiol is a more effective bone-sparing and anabolic agent than 5alpha-dihydrotestosterone. J Bone Miner Res 2002; 17: 2080-6. (Pubitemid 35239209)
110. Limer KL, Pye SR, Thomson W, Boonen S, Borghs H, et al. EMAS Study Group. Genetic variation in sex hormone genes influences heel ultrasound parameters in middle-aged and elderly men: results from the European Male Aging Study (EMAS). J Bone Miner Res 2009; 24: 314-23.
111. Holliday KL, Pye SR, Thomson W, Boonen S, Borghs H, et al. EMAS Study Group. The ESR1 (6q25) locus is associated with calcaneal ultrasound parameters and radial volumetric bone mineral density in European men. Plos One 2011; 6: e22037.
112. Huhtaniemi IT, Pye SR, Holliday KL, Thomson W, O'Neill TW, et al. European Male Aging Study Group. Effect of polymorphisms in selected genes involved in pituitary-testicular function on reproductive hormones and phenotype in aging men. J Clin Endocrinol Metab 2010; 95: 1898-908.
113. Huhtaniemi IT, Pye SR, Limer KL, Thomson W, O'Neill TW, et al. European Male Aging Study Group. Increased estrogen rather than decreased androgen action is associated with longer androgen receptor CAG repeats. J Clin Endocrinol Metab 2009; 94: 277-84.
114. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-64. (Pubitemid 40096612)
115. Smith MR, Goode M, Zietman AL, Mcgovern FJ, Lee H, et al. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 2004; 22: 2546-53. (Pubitemid 41103742)
116. Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, Mcfadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004; 171: 2272-6. (Pubitemid 38625450)
117. Wadhwa VK, Weston R, Mistry R, Parr NJ. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 2009; 104: 800-5.
118. Burnett-Bowie SA, Mckay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab 2009; 94: 4785-92.
119. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000; 106: 1553-60. (Pubitemid 32038592)
120. Yu E, Taylor A, Wulcyzn K, Webb M, Perros N, et al. Hypogonadism with estrogen removal (Her): differential effects of androgens and estrogens on bone microarchitecture in adult men. J Bone Mineral Res 2012; 27: S66.
121. Vandenput L, Ederveen AG, Erben RG, Stahr K, Swinnen JV, et al. Testosterone prevents orchidectomy-induced bone loss in estrogen receptor-alpha knockout mice. Biochem Biophys Res Commun 2001; 285: 70-6. (Pubitemid 32916121)
122. Mellstrom D, Johnell O, Ljunggren O, Eriksson AL, Lorentzon M, et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MROS Sweden. J Bone Miner Res 2006; 21: 529-35.
123. Meier C, Nguyen TV, Handelsman DJ, Schindler C, Kushnir MM, et al. Endogenous sex hormones and incident fracture risk in older men: The Dubbo Osteoporosis Epidemiology Study. Arch Intern Med 2008; 168: 47-54.
124. van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 2000; 85: 3276-82.
125. Tajar A, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR, et al. EMAS Group. Characteristics of androgen deficiency in late-onset hypogonadism: results from the european male aging study (EMAS). J Clin Endocrinol Metab 2012; 97: 1508-16.
126. Amin S, Zhang Y, Felson DT, Sawin CT, Hannan MT, et al. Estradiol, testosterone, and the risk for hip fractures in elderly men from the framingham study. Am J Med 2006; 119: 426-33.
127. Vandenput L, Swinnen JV, Boonen S, Van Herck E, Erben RG, et al. Role of the androgen receptor in skeletal homeostasis: the androgen-resistant testicular feminized male mouse model. J Bone Miner Res 2004; 19: 1462-70. (Pubitemid 41094347)
128. Rochira V, Zirilli L, Madeo B, Aranda C, Caffagni G, et al. skeletal effects of long-term estrogen and testosterone replacement treatment in a man with congenital aromatase deficiency: evidences of a priming effect of estrogen for sex steroids action on bone. Bone 2007; 40: 1662-8. (Pubitemid 46779001)
129. Leblanc ES, Nielson CM, Marshall LM, Lapidus JA, Barrett-Connor E, et al. Osteoporotic Fractures in Men Study Group. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab 2009; 94: 3337-46.
130. Cauley JA, Ewing SK, Taylor BC, Fink HA, Ensrud KE, et al. Osteoporotic Fractures in Men Study (MrOS) Research Group. Sex steroid hormones in older men: longitudinal associations with 4.5-year change in hip bone mineral density - the osteoporotic fractures in men study. J Clin Endocrinol Metab 2010; 95: 4314-23.
131. Vanbillemont G, Lapauw B, Bogaert V, Goemaere S, Zmierczak HG, et al. Sex hormone-binding globulin as an independent determinant of cortical bone status in men at the age of peak bone mass. J Clin Endocrinol Metab 2010; 95: 1579-86.
132. Lorentzon M, Swanson C, Andersson N, Mellstrom D, Ohlsson C. Free testosterone is a positive, whereas free estradiol is a negative, predictor of cortical bone size in young swedish men: The GOOD study. J Bone Miner Res 2005; 20: 1334-41. (Pubitemid 41033517)
133. Eriksson AL, Lorentzon M, Mellstrom D, Vandenput L, Swanson C, et al. SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab 2006; 91: 5029-37. (Pubitemid 44917346)
134. Center JR, Nguyen TV, Sambrook PN, Eisman JA. Hormonal and biochemical parameters and osteoporotic fractures in elderly men. J Bone Miner Res 2000; 15: 1405-11. (Pubitemid 30413875)
135. Khosla S. Editorial: sex hormone binding globulin: inhibitor or facilitator (or both) of sex steroid action? J Clin Endocrinol Metab 2006; 91: 4764-6. (Pubitemid 44917303)
136. Swanson C, Lorentzon M, Vandenput L, Labrie F, Rane A, et al. Sex steroid levels and cortical bone size in young men are associated with a uridine diphosphate glucuronosyltransferase 2B7 polymorphism (H268Y). J Clin Endocrinol Metab 2007; 92: 3697-704. (Pubitemid 47435358)
137. Lorentzon M, Eriksson AL, Mellstrom D, Ohlsson C. The COMT Val158met polymorphism is associated with peak BMD in men. J Bone Miner Res 2004; 19: 2005-11. (Pubitemid 41103415)
138. Eriksson AL, Mellstrom D, Lorentzon M, Orwoll ES, Redlund-Johnell I, et al. The COMT Val158met polymorphism is associated with prevalent fractures in swedish men. Bone 2008; 42: 107-12.
139. Lorentzon M, Eriksson AL, Nilsson S, Mellstrom D, Ohlsson C. Association
140. Stolk L, van Meurs JB, Jhamai M, Arp PP, van Leeuwen JP, et al. The catechol-o-methyltransferase met158 low-activity allele and association with nonvertebral fracture risk in elderly men. J Clin Endocrinol Metab 2007; 92: 3206-12. (Pubitemid 47236393)
141. Issa S, Schnabel D, Feix M, Wolf L, Schaefer HE, et al. Human osteoblast-like cells express predominantly steroid 5alpha-reductase type 1. J Clin Endocrinol Metab 2002; 87: 5401-7. (Pubitemid 36034333)
142. Tollin SR, Rosen HN, Zurowski K, Saltzman B, Zeind AJ, et al. Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia - A Clinical Research Center Study. J Clin Endocrinol Metab 1996; 81: 1031-4. (Pubitemid 26083967)
143. Matsumoto AM, Tenover L, Mcclung M, Mobley D, Geller J, et al. Pless Study Group. The long-term effect of specific type ii 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol 2002; 167: 2105-8. (Pubitemid 34309674)
144. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89: 503-10. (Pubitemid 38269849)
145. Amory JK, Anawalt BD, Matsumoto AM, Page ST, Bremner WJ, et al. The effect of 5α-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. J Urol 2008; 179: 2333-8.
146. Jacobsen SJ, Cheetham TC, Haque R, Shi JM, Loo RK. Association between 5-alpha reductase inhibition and risk of hip fracture. JAMA 2008; 300: 1660-4.
147. Vestergaard P, Rejnmark L, Mosekilde L. Risk of fractures associated with treatment for benign prostate hyperplasia in men. Osteoporos Int 2011; 22: 731-7.
148. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, et al. Exogenous testosterone (t) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005; 90: 1502-10. (Pubitemid 40464011)
149. Windahl SH, Andersson N, Borjesson AE, Swanson C, Svensson J, et al. Reduced bone mass and muscle strength in male 5alpha-reductase type 1 inactivated mice. Plos One 2011; 6: e21402.
150. Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003; 44: 82-8. (Pubitemid 36741378)
151. Bhasin S, Travison TG, Storer TW, Lakshman K, Kaushik M, et al. Effect of testosterone supplementation with and without a dual 5alpha-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. JAMA 2012; 307: 931-9.
152. Meier C, Liu PY, Ly LP, De Winter-Modzelewski J, Jimenez M, et al. Recombinant human chorionic gonadotropin but not dihydrotestosterone alone stimulates osteoblastic collagen synthesis in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 2004; 89: 3033-41. (Pubitemid 38766405)
153. Idan A, Griffiths KA, Harwood DT, Seibel MJ, Turner L, et al. Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. Ann Intern Med 2010; 153: 621-32.
154. Moverare S, Venken K, Eriksson AL, Andersson N, Skrtic S, et al. Differential effects on bone of estrogen receptor alpha and androgen receptor activation in orchidectomized adult male mice. Proc Natl Acad Sci U S A 2003; 100: 13573-8. (Pubitemid 37448563)
155. Tivesten A, Moverare-Skrtic S, Chagin A, Venken K, Salmon P, et al. Additive protective effects of estrogen and androgen treatment on trabecular bone in ovariectomized rats. J Bone Miner Res 2004; 19: 1833-9. (Pubitemid 41103435)
156. Venken K, De Gendt K, Boonen S, Ophoff J, Bouillon R, et al. Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: a study in the androgen receptor knockout mouse model. J Bone Miner Res 2006; 21: 576-85.
157. Sims NA, Dupont S, Krust A, Clement-Lacroix P, Minet D, et al. Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males. Bone 2002; 30: 18-25. (Pubitemid 34044296)
158. Maclean HE, Moore AJ, Sastra SA, Morris HA, Ghasem-Zadeh A, et al. DNA-binding-dependent androgen receptor signaling contributes to gender differences and has physiological actions in males and females. J Endocrinol 2010; 206: 93-103.
159. Windahl SH, Vidal O, Andersson G, Gustafsson JA, Ohlsson C. Increased cortical bone mineral content but unchanged trabecular bone mineral density in female erbeta(-/-) mice. J Clin Invest 1999; 104: 895-901. (Pubitemid 29536339)
160. Sims NA, Clement-Lacroix P, Minet D, Fraslon-Vanhulle C, Gaillard-Kelly M, et al. A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptor-deficient mice. J Clin Invest 2003; 111: 1319-27. (Pubitemid 36554702)
161. Kawano H, Sato T, Yamada T, Matsumoto T, Sekine K, et al. Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci U S A 2003; 100: 9416-21. (Pubitemid 37033943)
162. Chiang C, Chiu M, Moore AJ, Anderson PH, Ghasem-Zadeh A, et al. Mineralization and bone resorption are regulated by the androgen receptor in male mice. J Bone Miner Res 2009; 24: 621-31.
163. Notini AJ, Mcmanus JF, Moore A, Bouxsein M, Jimenez M, et al. Osteoblast deletion of exon 3 of the androgen receptor gene results in trabecular bone loss in adult male mice. J Bone Miner Res 2007; 22: 347-56. (Pubitemid 46797117)
164. Wiren KM, Zhang XW, Toombs AR, Kasparcova V, Gentile MA, et al. Targeted overexpression of androgen receptor in osteoblasts: unexpected complex bone phenotype in growing animals. Endocrinology 2004; 145: 3507-22. (Pubitemid 38830023)
165. Wiren KM, Semirale AA, Zhang XW, Woo A, Tommasini SM, et al. Targeting of androgen receptor in bone reveals a lack of androgen anabolic action and inhibition of osteogenesis: a model for compartment-specific androgen action in the skeleton. Bone 2008; 43: 440-51.
166. Sinnesael M, Claessens F, Laurent M, Dubois V, Boonen S, et al. Androgen receptor (AR) in osteocytes is important for the maintenance of male skeletal integrity: evidence from targeted AR disruption in mouse osteocytes. J Bone Miner Res 2012; 27: 2535-43.
167. Abu EO, Horner A, Kusec V, Triffitt JT, Compston JE. The localization of androgen receptors in human bone. J Clin Endocrinol Metab 1997; 82: 3493-7. (Pubitemid 27419110)
168. Turner AG, Notini AJ, Chiu WS, Hodge J, Nicholson G, et al. Androgen receptor expression and function in osteoclasts. Open Physiol J 2008; 1.
169. Huber DM, Bendixen AC, Pathrose P, Srivastava S, Dienger KM, et al. Androgens suppress osteoclast formation induced by rankl and macrophage-colony stimulating factor. Endocrinology 2001; 142: 3800-8. (Pubitemid 32802650)
170. Pederson L, Kremer M, Judd J, Pascoe D, Spelsberg TC, et al. Androgens regulate bone resorption activity of isolated osteoclasts in vitro. Proc Natl Acad Sci U S A 1999; 96: 505-10. (Pubitemid 29061238)
171. Michael H, Harkonen PL, Vaananen HK, Hentunen TA. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res 2005; 20: 2224-32. (Pubitemid 41698785)
172. Nakamura T, Watanabe T, Nakamichi Y, Fukuda T, Matsumoto T, et al. Genetic evidence of androgen receptor function in osteoclasts: generation and characterization of osteoclast-specific androgen receptor knockout mice. J Bone Miner Res 2004; 19: S3.
173. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of fas ligand in osteoclasts. Cell 2007; 130: 811-23. (Pubitemid 47332572)
174. Martin-Millan M, Almeida M, Ambrogini E, Han L, Zhao H, et al. The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol 2010; 24: 323-34.
175. Sjogren K, Lagerquist M, Moverare-Skrtic S, Andersson N, Windahl SH, et al. Elevated aromatase expression in osteoblasts leads to increased bone mass without systemic adverse effects. J Bone Miner Res 2009; 24: 1263-70.
176. Almeida M, Iyer S, Martin-Millan M, Bartell SM, Han L, et al. Estrogen receptor-alpha signaling in osteoblast progenitors stimulates cortical bone accrual. J Clin Invest 2013; 123: 394-404.
177. Maatta JA, Buki KG, Gu G, Alanne MH, Vaaraniemi J, et al. Inactivation of estrogen receptor alpha in bone-forming cells induces bone loss in female mice. FASEB J 2013; 27: 478-88.
178. Windahl SH, Borjesson AE, Farman HH, Engdahl C, Moverare-Skrtic S, et al. Estrogen receptor-alpha in osteocytes is important for trabecular bone formation in male mice. Proc Natl Acad Sci U S A 2013; 110: 2294-9.
179. Lee K, Jessop H, Suswillo R, Zaman G, Lanyon L. Endocrinology: bone adaptation requires oestrogen receptor-alpha. Nature 2003; 424: 389. (Pubitemid 36917478)
180. Callewaert F, Bakker A, Schrooten J, Van Meerbeek B, Verhoeven G, et al. Androgen receptor disruption increases the osteogenic response to mechanical loading in male mice. J Bone Miner Res 2010; 25: 124-31.
181. MacLean HE, Chiu WS, Notini AJ, Axell AM, Davey RA, et al. Impaired skeletal muscle development and function in male, but not female, genomic androgen receptor knockout mice. FASEB J 2008; 22: 2676-89.
182. Ophoff J, Van Proeyen K, Callewaert F, De Gendt K, De Bock K, et al. Androgen signaling in myocytes contributes to the maintenance of muscle mass and fiber type regulation but not to muscle strength or fatigue. Endocrinology 2009; 150: 3558-66.
183. Chambon C, Duteil D, Vignaud A, Ferry A, Messaddeq N, et al. Myocytic androgen receptor controls the strength but not the mass of limb muscles. Proc Natl Acad Sci U S A 2010; 107: 14327-32.
184. Dubois V, Laurent M, Boonen S, Vanderschueren D, Claessens F. Androgens and skeletal muscle: cellular and molecular action mechanisms underlying the anabolic actions. Cell Mol Life Sci 2012; 69: 1651-67.
185. Gielen E, Verschueren S, O'Neill TW, Pye SR, O'connell MD, et al. Musculoskeletal frailty: a geriatric syndrome at the core of fracture occurrence in older age. Calcif Tissue Int 2012; 91: 161-77.
186. Verschueren S, Gielen E, O'Neill TW, Pye SR, Adams JE, et al. Sarcopenia and its relationship with bone mineral density in middle-aged and elderly european men. Osteoporos Int 2013; 24: 87-98.
187. Ohlsson C, Engdahl C, Borjesson AE, Windahl SH, Studer E, et al. Estrogen receptor-alpha expression in neuronal cells affects bone mass. Proc Natl Acad Sci U S A 2012; 109: 983-8.
188. Raskin K, de Gendt K, Duittoz A, Liere P, Verhoeven G, et al. Conditional inactivation of androgen receptor gene in the nervous system: effects on male behavioral and neuroendocrine responses. J Neurosci 2009; 29: 4461-70.
189. Olson LE, Ohlsson C, Mohan S. The role of GH/IGF-I-mediated mechanisms in sex differences in cortical bone size in mice. Calcif Tissue Int 2011; 88: 1-8.